David Morgan

David Morgan is the Chief Executive Officer of Zephyr AI. Prior to joining Zephyr in January 2022, he served as a Senior Vice President for Eurofins Scientific Group running a portfolio of diagnostic, biopharma and biotechnology companies. He remains a board member of Eurofins Transplant Genomics, Viacor BioPharma Services, and Viacor Eurofins Clinical Diagnostics. Mr. Morgan is a healthcare executive with over 20 years of experience running various-sized private companies and large divisions of public companies. He has also served on several for-profit and not-for-profit Boards of Directors. Prior to joining Viracor, Mr. Morgan was President and CEO of VantagePoint Holdings, Inc., a private equity-backed group of diagnostic companies that were sold to Sonic Healthcare in January of 2017. Before his time at Vantage Point Holdings, Mr. Morgan held senior executive positions at Cogent Healthcare, Beacon Bay Holdings, and Laboratory Corporation of America. Mr. Morgan began his career with US LABS, Inc., where he held several management positions culminating as Vice President of Operations when the company was sold to LabCorp in 2006. Following the acquisition by LabCorp, Mr. Morgan remained with the company where he held several general management positions as both Vice President and Senior Vice President. Mr. Morgan was responsible for integrating LabCorp’s many Oncology and Anatomic Pathology companies into its Oncology Division, which later became known as Integrated Oncology. Prior to his career in healthcare, Mr. Morgan was a 10 year veteran of the United States Marine Corps and remained in the Marine Corps Reserve until retiring as Colonel in 2020. He holds a Bachelor’s degree from University of Pittsburgh and a Master’s degree from Central Michigan University.
Speaking In
11:00 AM - 12:00 PM (PDT)
Tuesday, June 14
Life sciences and healthcare companies are leveraging machine learning and AI for new advancements…